Current Status of Biosimilars in US, Europe and Canada
July 28, 2015 - Online event CA USCompliance4all
support@compliance4All.com
Phone:8004479407
Fax:302-288-6884
Understanding this fast developing area is critical. How will approvals be handled. Will indications be able to be bridged from a clinical study in one therapeutic area to another. Will interchangeability be recognized? How are some products / companies being successful? These are all questions in this complex landscape. We will address the current thinking on each and provide an update in terms of what is being done by whom in terms of development in this area. Areas Covered in the Session: Biosimilar legislation in the US Purple Book Marketing applications filed using the biosimilar route or other routes Interchangeability requirements Status of subsequent entry biologics in Canada Review of two products that have been successful in Canada by two different routes Existing guidelines in Europe Review of approvals in Europe Interchangeability for infliximab in Denmark Public policy driving biosimilars in France Ongoing development work on biosimilars worldwide Read more : http://www.compliance4all.com/control/w_product/~product_id=500354LIVE